91桃色

The tumor microenvironment (TME) is a complex network of cells, extracellular matrix components, and signaling molecules that surround and interact with cancer cells. In recent years, it has become increasingly evident that inflammation plays a pivotal role in shaping the TME and influencing cancer progression. Chronic inflammation within the TME can both promote tumor growth and serve as a key mediator of cancer metastasis. Moreover, inflammatory signaling is now recognized as a major factor influencing the effectiveness of immunotherapies, which have revolutionized cancer treatment. Understanding how inflammatory signals within the TME impact immune cell function and therapy response is essential for optimizing immunotherapy strategies. This article explores the role of inflammatory signaling in the TME and its implications for the success or failure of immunotherapy in cancer treatment [1].

Description

The tumor microenvironment and inflammatory signaling

Chronic inflammation in the tumor microenvironment: The TME is characterized by chronic inflammation, which results from both the immune response to the tumor and the intrinsic properties of the tumor itself. Tumor cells often release various pro-inflammatory cytokines, chemokines, and growth factors that recruit immune cells such as macrophages, neutrophils, T cells, and dendritic cells to the site of the tumor. In response to these signals, the immune cells become activated and release additional inflammatory mediators, further contributing to the inflammatory milieu. While inflammation is initially protective, chronic inflammation can lead to the promotion of tumor growth, angiogenesis, and immune evasion [2].

Key pro-inflammatory molecules in the TME include cytokines like tumor necrosis factor (TNF)-α, interleukins (such as IL-6, IL-1β), and chemokines like CCL2, which recruit immune cells and facilitate tissue remodeling. These inflammatory mediators can also activate several molecular signaling pathways, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), Janus kinase-signal transducer and activator of transcription (JAK-STAT), and mitogen-activated protein kinase (MAPK), all of which promote tumor cell survival, proliferation, and metastasis. Chronic inflammation in the TME thus creates a pro-tumorigenic environment that aids in tumor progression and immune suppression [3].

Immune cell dynamics and inflammatory mediators: Within the TME, inflammation modulates the function and recruitment of various immune cells, which can have a dual effect on cancer progression. On the one hand, pro-inflammatory cytokines can activate immune cells like T lymphocytes and natural killer (NK) cells, which have the potential to recognize and destroy tumor cells. On the other hand, chronic inflammation often leads to immune suppression, which hinders anti-tumor immunity [4].

Tumor-associated macrophages (TAMs): TAMs, which are often recruited by inflammatory signals, play a significant role in promoting tumor progression. In a pro-inflammatory environment, TAMs can adopt a phenotype that supports tumor growth by secreting cytokines such as IL-10 and transforming growth factor-beta (TGF-β), which suppress T cell activity and promote immune evasion [5]. They can also produce matrix metalloproteinases (MMPs) that degrade the extracellular matrix, allowing tumor cells to invade surrounding tissues.

Regulatory T cells (Tregs): Chronic inflammation also promotes the accumulation of Tregs, a subset of immune cells that suppress the anti-tumor immune response. Elevated levels of Tregs in the TME have been associated with poor prognosis in various cancers, as they dampen the activity of cytotoxic T cells and NK cells, allowing tumors to evade immune surveillance.

Myeloid-derived suppressor cells (MDSCs): MDSCs are another immune cell population that is expanded in inflamed tumor tissues. MDSCs suppress the activity of effector T cells and can induce an immunosuppressive microenvironment that favors tumor progression [6].

Inflammatory signaling pathways and immune evasion: Inflammatory signaling pathways play a crucial role in immune evasion within the TME. One of the most well-studied pathways is the NF-κB pathway, which is activated by inflammatory cytokines and plays a role in tumor cell survival, angiogenesis, and immune suppression. NF-κB signaling can promote the expression of immune checkpoint molecules such as programmed cell death protein 1 (PD-1) and its ligand (PD-L1), which act to inhibit the immune response by downregulating T cell activity [7].

Similarly, the JAK-STAT pathway, often activated by inflammatory cytokines like IL-6, contributes to immune evasion by promoting the expansion of immunosuppressive cells such as Tregs and MDSCs. The activation of these pathways by inflammatory signals within the TME thus undermines the efficacy of immune responses against tumors, complicating immunotherapy strategies.

Inflammatory signaling and immunotherapy response

Immunotherapies, such as immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors, CTLA-4 inhibitors), CAR-T cell therapies, and cancer vaccines, have dramatically improved treatment outcomes for various cancers. However, the presence of inflammation in the TME can significantly impact the response to these therapies [8].

Immunotherapy and tumor inflammation: Immune checkpoint inhibitors, which block inhibitory receptors like PD-1 or CTLA-4 on T cells, have shown remarkable success in treating cancers such as melanoma, lung cancer, and head and neck cancers. These therapies work by reinvigorating exhausted T cells, allowing them to mount an effective anti-tumor response. However, in inflamed tumors, chronic inflammatory signals can induce immune suppression through the upregulation of immune checkpoint molecules like PD-L1. Elevated PD-L1 expression on tumor cells and immune cells in the TME can inhibit T cell activation, reducing the effectiveness of checkpoint inhibitors.

Additionally, the inflammatory microenvironment can influence the tumor’s ability to respond to adoptive T cell therapies, such as CAR-T cells. Chronic inflammation can impair the infiltration and function of these engineered T cells within the TME by promoting an immunosuppressive environment and enhancing the recruitment of suppressive immune cells, such as MDSCs and Tregs.

Targeting inflammatory pathways to enhance immunotherapy: Given the impact of inflammatory signaling on immune evasion, combining immunotherapies with agents that target specific inflammatory pathways represents a promising strategy to improve treatment outcomes. For example, blocking NF-κB signaling or inhibiting the JAK-STAT pathway could reduce the expression of immune checkpoint molecules and decrease immune suppression within the TME. Additionally, targeting pro-inflammatory cytokines such as IL-6 or TNF-α could help to reprogram the immune microenvironment, making it more permissive to immune-based therapies [9].

There is also ongoing research into combining immune checkpoint inhibitors with anti-inflammatory drugs or inhibitors of tumor-associated inflammation [10]. Such combinatory approaches aim to both enhance anti-tumor immunity and overcome the immune resistance that arises from chronic inflammation in the TME.

Conclusion

Inflammatory signaling within the tumor microenvironment plays a pivotal role in cancer progression and influences the response to immunotherapy. While inflammation can initially act as a defense mechanism, its chronic activation in the TME ultimately creates an environment that supports tumor growth, immune suppression, and metastasis. Tumor-associated inflammation activates several molecular pathways that facilitate immune evasion and reduce the effectiveness of immune therapies. However, understanding the intricate relationship between inflammatory signaling and immune response offers opportunities to optimize immunotherapy. By targeting key inflammatory pathways, researchers and clinicians can develop combination therapies that not only boost immune responses but also reprogram the TME to become more responsive to immunotherapy, offering hope for improved outcomes in cancer treatment.

Acknowledgement

None

Conflict of Interest

None

1. Bimonte S, Leongito M, Barbieri A, Vecchio V, Barbieri M, et al. (2015) . Infect Agents Cancer 10: 22.

, ,

2. Kostin S, McDonald D, McFadden D (2012) . J Surg Res 77: 255-262.

, ,

3. Rao V, Agarwal S (2000) . J Am Coll Nutrit 19: 563-569.

, ,

4. Li F, Awale S, Tezuka Y, Esumi H, Kadota S (2010) . J Nat Prod 73: 623-627.

, ,

5. Sawicka D, Car H, Borawska M, Nikli艅ski J (2012) . Folia Histochem Cytobiol 50: 25-37.

, ,

6. Yin T, Shi P, Gou S, Shen Q, Wang C (2014) . Plos One 9: e114581.

,

7. Li Y, Wicha M, Schwartz S, Sun D (2011. J Nutr Biochem 22: 799-806.

, ,

8. Suzuki R, Kang Y, Li X, Roife D, Zhang R, et al. (2014) . Anticancer Res 34: 4685-4692.

,

9. Ma J, Cheng L, Liu H, Sarkar F, Xia J, et al. (2013) . Current Drug Targets 14: 1150-1156.

, ,

10. El-Rayes B, Ali S, Ali I, Philip P, Abbruzzese J, et al. (2006) . Cancer Res 66: 10553-10559.

, ,